Alnylam Grants New InterfeRx(TM) Intellectual Property License to Calando for Development and...

Monday July 21, 8:00 am ET - New Target-Specific License Provides Non-Exclusive Access to Alnylam Intellectual Property for an RNAi Therapeutic Product - CAMBRIDGE, Mass. & PASADENA, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, today announced that it has granted Calando Pharmaceuticals Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR - News ), a new target-specific InterfeRx™ license to discover, develop, and commercialize a synthetic siRNA directed toward an undisclosed cancer gene target. The new non-exclusive, gene-specific license agreement includes an Alnylam right of first negotiation to opt-in for co-development and co-commercialization of the RNAi therapeutic product in the U.S. market. Detailed financial terms were... [read full story]